Menu

Pipeline Overview*

Pipeline Overview

Drug2 Indication Pre-clinical Phase i/ii Phase iii Marketed
TALICIA® (RHB-105) H. pylori infections
Confirmatory Phase III study ongoing
RHB-104 Crohn's disease
Phase III MAP US study & Phase III MAP US2 extension study ongoing
RHB-204 NTM infections
Pivotal Phase III study planned
BEKINDA®
(RHB-102)
Gastroenteritis & gastritis
Positive results from Phase III U.S. study
IBS-D
Positive results from Phase II U.S. study
RHB-106 Bowel cleanser
WW rights licensed to Salix Pharmaceuticals
YELIVA® (ABC294640) Multiple indications
Cholangiocarcinoma and other indications
RHB-107 (MESUPRON) Oncology/GI
Completed multiple clinical studies
Other
RIZAPORT®
(RHB-103)
Migraine
U.S. NDA filed - re-submission of NDA planned following CRL
EUROPEAN MAA APPROVED UNDER THE EUROPEAN DECENTRALIZED PROCEDURE
* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies 2 BEKINDA®, YELIVA® and TALICIA® are proposed tradenames which are subject to FDA review and approval